5 Biotech Stocks Rising on Unusual Volume

Traders should now look for long-biased trades in AEZS as long as it's trending above today's low of $1.90, and then once it sustains a move or close above those breakout levels with volume that hits near or above 5700,360 shares. If that breakout triggers soon, then AEZS will set up to re-fill some of its previous gap down zone from October that started above $3. Any high-volume move above its 50-day at $2.98 will then put $3.55 to $4 into focus for AEZS.

Endocyte (ECYT)

This is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnose. This stock is trading up 9.9% to $8.52 in recent trading.

Today's Range: $7.75-$8.51

52-Week Range: $3.02-$11.11

Volume: 242,000

Three-Month Average Volume: 226,471

Shares of ECYT are soaring today after Summer Street started coverage on the stock with a buy rating and an $18 price target.

From a technical perspective, ECYT is exploding higher here right near its 200-day moving average of $7.39 with above-average volume. This move has also pushed ECYT into breakout territory, since the stock has moved above some near-term overhead resistance at $8.24. This move is coming after ECYT recently downtrended from a high of $10.97 to its recent low of $7.50.

Traders should now look for long-biased trades in ECYT as long as it's trending above its 200-day at $7.39, and then once it sustains a move or close above $8.24 with volume that hits near or above 226,471 shares. If ECYT can maintain that trend, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $9.50 to $10. Any high-volume move above those levels will then put $10.68 to $10.97 into focus for ECYT.

Dynavax Technologies (DVAX)

This is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. This stock is trading up 8.7% to $2.90 in recent trading.

« First ‹ Previous 1 2 3 4 Next › Last »